(2019) (166) evaluated the efficacy and safety of RTX in patients with refractory MG (N = 56, 39 patients were anti- AChR antibody positive, 14 patients were anti-MuSK antibody positive, and 3 patients were seronegative). Here, MUSK is linked to myasthenia gravis.